Advertisement

Advertisement
Gynecologic Cancers

Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer

The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced...

Lung Cancer

T-DXd in HER2-Overexpressing Unresectable or Metastatic NSCLC

As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer...

Thyroid Cancer

New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk

Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study...


Advertisement
Solid Tumors

Cabozantinib in Advanced Adrenocortical Carcinoma

In a single-center phase II trial reported in The Lancet Oncology, Campbell et al found that cabozantinib monotherapy showed activity in adult patients...

Lung Cancer

NSCLC: Neoadjuvant Chemoimmunotherapy vs Neoadjuvant Chemotherapy

In a systematic review and meta-analysis reported in JAMA Oncology, Sorin et al found that neoadjuvant chemoimmunotherapy was associated with better...

Advertisement
Advertisement




Sponsored Content


Breast Cancer

Terry P. Mamounas, MD, MPH, on Breast Cancer: Extended Aromatase Inhibitor Therapy

Breast Cancer
Survivorship

Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Who Received Chest Radiation

In an analysis from the Childhood Cancer Survivor Study (CCSS) and the Dutch Hodgkin Late Effects and LATER cohorts reported in the Journal of Clinical Oncology, Moskowitz et al developed a model for predicting the risk of breast cancer among childhood cancer survivors treated with chest...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Bladder Cancer
Immunotherapy

Matt D. Galsky, MD, on Bladder Cancer: Neoadjuvant Therapy With Gemcitabine, Cisplatin, and Nivolumab

Survivorship

Study Examines Barriers to Survivorship Care

Even among a large group of cancer survivors who were mostly insured, college-educated, and had annual incomes above the national average, up to 10% delayed care in the previous 12 months because they simply could not afford out-of-pocket expenses like copays and deductibles. These findings were...

Prostate Cancer

Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer

Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Pembrolizumab vs Placebo in Adjuvant Treatment

Breast Cancer
Immunotherapy

Noninvasive Imaging Biomarker and Pathologic Complete Response to Neoadjuvant Pertuzumab/Trastuzumab in HER2-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MD, and colleagues, updated results of the phase II TBCRC026 trial indicate an association of early F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (F-18 FDG PET/CT) maximum standardized uptake value...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter